Daniel Ibrahim

Dr. Daniel Ibrahim leads a research group at the Max Planck Institute for Molecular Genetics (MPIMG) and the Berlin Institute of Health (BIH) Center for Regenerative Therapies. His work focuses on the chromatin biology of gene regulatory domains, combining genome engineering (CRISPR-Cas9, RMCE) with functional genomics to study how chromatin structure controls gene expression in development and disease.

• Primary Affiliation: Research Group Leader, MPIMG
• Collaboration: BIH Center for Regenerative Therapies
• Research Focus: 3D chromatin organization, TADs, enhancer-promoter interactions

Research Highlights: Dr. Ibrahim's team investigates how structural genomic variations (e.g., TAD rearrangements, CTCF site deletions) lead to gene misexpression in congenital disorders and cancer. They pioneered synthetic biology approaches for BAC-sized transgene assembly and mouse embryonic stem cell engineering to model disease mechanisms.

Publications: His work spans 3D genome biology, transcription factor dysfunction in disease (e.g., HOXD13 mutations), and advanced genome editing techniques. Recent studies explore evolutionary conservation of regulatory elements and CRISPR-based transgene integration methods.

Team Members: PhD students Blanka Majchrzycka, Mai Phan, Andreas Magg, and Milan Antonovic contribute to ongoing projects in chromatin dynamics and disease modeling.